Showing 7941-7950 of 8351 results for "".
- Cellfina Cleared to Treat Cellulite for Up to Two Yearshttps://practicaldermatology.com/news/cellfina-cleared-to-treat-cellulite-for-up-to-two-years/2458898/The Cellfina System from Ulthera, Inc. has received FDA clearance for the long-term improvement in the appearance of cellulite on the buttocks and thighs with no loss of benefit for up to 2 years. Ulthera is a a wholly-owned subsidiary of Merz, Inc. The
- National Psoriasis Foundation Launches Patient-centered Research Platformhttps://practicaldermatology.com/news/national-psoriasis-foundation-launches-patient-centered-research-platform/2458902/Patients with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation’s patient-centered research network called Citizen Pscientist. This online, interactive community, all
- Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designationhttps://practicaldermatology.com/news/novartis-combination-therapy-tafinlar-and-mekinist-receive-fda-priority-review-designation/2458904/The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Also, the Committee for Medi
- Organogenesis Launches PuraPly Wound Management Productshttps://practicaldermatology.com/news/organogenesis-launches-puraply-wound-management-products/2458905/Organogenesis Inc. launched its new PuraPly™ wound management products, including PuraPly Antimicrobial (PuraPly AM), the first FDA-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent. PuraPly and PuraPly AM are the la
- Investigational Foam May Offer Itch Relief for Psoriasis Patientshttps://practicaldermatology.com/news/investigational-foam-may-offer-itch-relief-for-psoriasis-patients/2458931/An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congress of Dermatology. According to the Phase 3 clinical trial, 426 psoriasis patients were split int
- Skin Cancer Foundation Hosts Young Professionals Partyhttps://practicaldermatology.com/news/skin-cancer-foundation-hosts-young-professionals-party/2458943/The Skin Cancer Foundation hosted its 2015 Young Professionals Party in New York City on Thursday, May 14 at the Press Lounge rooftop bar at the Ink 48 Hotel. The event united more than 300 young professionals from the beauty and medical industries in the fight a
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in
- Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Todayhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-data-on-pv-10-to-be-presented-at-hemonc-today/2458972/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous
- Novan Secures $50 Million Private Financinghttps://practicaldermatology.com/news/novan-secures-50-million-private-financing/2458973/Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing. New investor Malin Corporation Plc. (MLC: ISE) functioned as the cornerston
- Suneva Medical Introduces Regenica Recovery Gelhttps://practicaldermatology.com/news/suneva-medical-introduces-regenica-recovery-gel/2458983/Suneva Medical, Inc. introduced Regenica® Recovery Gel, a new addition to the Regenica® skin care system, during the American Academy of Dermatology Annual Meeting. Regenica® Recovery Gel is a soothing balm that is specially formulated to help quickly heal damaged skin. It infuses Mul